Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06442995
Other study ID # PO24038*
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date July 2024
Est. completion date August 2025

Study information

Verified date June 2024
Source CHU de Reims
Contact Maxime Riffault
Phone 00336 79 63 29 55
Email mriffault@chu-reims.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Peri-medullary anesthesia is the preferred anesthetic technique for Caesarean surgery. Compared with general anesthesia, it reduces maternal and fetal morbidity and mortality, as well as postoperative pain. However, this technique exposes the patient to the adverse effects of peri-medullary morphine, particularly the risk of postoperative urinary retention. Urinary retention during the first 72 hours after Caesarean section affects around 33% of parturients. This is a particularly debilitating event for parturients, exposing them to the risk of further urinary catheterization, increased theoretical risk of urinary tract infection, traumatic urethral injury, hindered accelerated rehabilitation and altered maternal satisfaction. Several studies have demonstrated the benefits of adding magnesium sulfate to epidural anesthesia for Caesarean sections, notably by reducing postoperative pain. Magnesium sulfate may also have a facilitating effect on postoperative micturition, thanks to its sympathicolytic effect. This hypothesis is supported by a retrospective study carried out in our maternity hospital, which showed a 15% reduction in post-Caesarean urinary retention when women were given magnesium sulfate in addition to the drugs traditionally used for epidurals. This little-known property needs to be clarified


Description:

The main objective of this study is to evaluate the efficacy of the addition of epidural magnesium sulfate in reducing the occurrence of acute post-Caesarean urine retention. In fact, the incidence of acute urine retention after epidural anaesthesia for Caesarean section is around 33%. Two encouraging studies suggest that adding magnesium sulfate to epidurals could reduce the incidence of acute urine retention by 15%. This study will be carried out on the obstetric population of the REIMS maternity hospital, starting in summer 2024. It is a randomized, double-blind, placebo-controlled clinical trial. The number of subjects required is calculated at 290 patients, with a power of 80% and an alpha risk of 5%. The statistical hypothesis is that magnesium sulfate reduces the incidence of acute urine retention by 15% compared with placebo (isotonic saline). Parturients will be informed of the study during a pre-anaesthetic consultation in the 6th month of pregnancy. Some of these patients will be scheduled for delivery by caesarean section. The remaining patients will be scheduled for a vaginal delivery, which may end up being an emergency caesarean section (10-15% of patients). After the Caesarean section, patients are taken to the post-procedure monitoring room, where they are monitored for 2 hours. It is at this point that patients are examined to verify the inclusion and non-inclusion criteria of the protocol. If the inclusion and non-inclusion criteria are met, our teams will provide patients with explanatory documents on our protocol, as well as a consent form for their signature. When the patient agrees to enter the protocol, the investigators randomize her to one of the following groups: - Group A: injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg - Group B: injection of morphine 2 mg into the epidural catheter + isotonic saline. Group B is the control group. This is the protocol we use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies. This reduces the parturient's postoperative pain for 20-24 hours. Group A will be the experimental group. Patients will be monitored in the post-natal care unit for 72 hours. The investigators will carry out the same monitoring and care as a parturient outside the protocol. Various data on diuresis, the quantity of urine in the bladder visualized by ultrasound, and the need for urinary catheterization will be recorded. Statistical analyses will determine whether the incidence of acute urine retention differs between each group.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 290
Est. completion date August 2025
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who have undergone scheduled or emergency Caesarean section surgery under extended epidural anesthesia or combined epidural and spinal anesthesia at the Reims University Hospital. - Patients who have just undergone caesarean section and have the epidural catheter in place in the post-interventional monitoring room (SSPI). - Patients who agree to take part in the research and have signed the informed consent form - Patients of legal age - Patients affiliated to a social security scheme Exclusion Criteria: - Minor patients - Patients protected by law - Patients allergic to local anesthetics, morphine or magnesium sulfate - Patients with severe renal insufficiency (GFR < 30 ml/min) - Patients with pre-pregnancy mictional disorders - Patients with an American Society of Anesthesiologists (ASA) score of 4 - Patients undergoing caesarean section under general anaesthesia, after failure of perimedullary anaesthesia - Patients with accidental intraoperative injury to the urinary tract - Patients who have received intravenous magnesium sulfate in the 24 hours preceding cesarean section

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Injection of 500 mg magnesium sulfate + 2 mg morphine into the epidural space
When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to the injection of morphine 2 mg into the epidural catheter + magnesium sulfate 500 mg
Injection of Isotonic saline + 2 mg morphine into the epidural space
When the patient agrees to enter the protocol, the investigators randomize the patient and proceed to Injection of morphine 2 mg into the epidural catheter + isotonic saline. This is the protocol the investigators use in daily practice for parturients who have undergone Caesarean section, in line with the French recommendations of anesthesia societies

Locations

Country Name City State
France Chu Reims Reims

Sponsors (1)

Lead Sponsor Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary diuresis 72 hours
See also
  Status Clinical Trial Phase
Withdrawn NCT05538273 - Optimal Management of Urinary Catheter in Gyn Onc
Recruiting NCT05065255 - Study of the Criteria for Choosing Speedicath Catheters During the Initiation of Self-catheterization
Completed NCT04236596 - Pudendal Nerve Mapping Towards Improved Neuromodulation for Urinary Retention N/A
Completed NCT05526651 - Improvement of Urinary Retention Symptoms With Electroacupuncture Therapy N/A
Not yet recruiting NCT06070545 - The Effect of Modified Supine Position on Urinary Elimination After Percutaneous Coronary Intervention N/A
Recruiting NCT03314025 - Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery Phase 2
Recruiting NCT05439902 - Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women N/A
Enrolling by invitation NCT05259800 - Peppermint Oil for Urinary Retention N/A
Recruiting NCT06417346 - Comparison of Laparoscopic and Open Inguinal Hernia Repair in Elderly Patients N/A
Completed NCT03296280 - Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
Completed NCT04715971 - Urinary Retention on an Acute Geriatric Hospitalisation Unit.
Completed NCT03302936 - Assessing Pyridium for Post-Sling Urinary Retention Phase 4
Completed NCT02886143 - Effect of Active vs. Passive Voiding Trials on Time to Discharge, Urinary Tract Infection, and Urinary Retention Phase 3
Completed NCT02749188 - Evaluation of Bladder Stimulation as a Noninvasive Technique of Urine Collection in Infant Who Have Not Acquired Walking N/A
Completed NCT01220362 - Effects of Thoracic Epidural Analgesia and Surgery on Lower Urinary Tract Function: A Randomized, Controlled Study N/A
Completed NCT01284361 - Comparison of Two Intermittent Urinary Catheters N/A
Terminated NCT00804557 - Efficacy And Safety Of The Uro-Ease® Urinary Catheter During Clean Intermittent Catheterization N/A
Terminated NCT00563485 - Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up N/A
Terminated NCT00563654 - Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up N/A
Terminated NCT04682366 - The Effect of Tamsulosin on Postoperative Urinary Retention Phase 4